Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 17/20 | 0.65 |
| ▸ | DPP4 | P27487 | 2/20 | 0.49 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227224 | 1.00 | NOTUM (0.65) | NOTUMDPP4SLC6A9 | |
| SCHEMBL1410444 | 0.99 | NOTUM (0.64) | NOTUMDPP4SLC6A9 | |
| SCHEMBL30772472 | 0.89 | NOTUM (0.51) | NOTUMDPP4 | |
| SCHEMBL1410443 | 0.89 | NOTUM (0.59) | NOTUMDPP4 | |
| SCHEMBL29141955 | 0.82 | NOTUM (0.64) | NOTUMDPP4SLC6A9 | |
| SCHEMBL29141957 | 0.81 | NOTUM (0.69) | NOTUMDPP4SLC6A9 | |
| SCHEMBL1410330 | 0.80 | NOTUM (0.59) | NOTUMDPP4SLC6A9 | |
| SCHEMBL1410617 | 0.80 | NOTUM (0.63) | NOTUMSLC6A9 | |
| SCHEMBL1409379 | 0.79 | FFAR4 (0.49) | NOTUMDPP4 | |
| SCHEMBL1410227 | 0.79 | NOTUM (0.66) | NOTUMDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241902-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO INC (US) | 2025-07-31 | — | — | US | claimed |
| US-20240248099-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | BELITE BIO, LLC | 2024-07-25 | — | — | US | claimed |
| EP-4340701-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | Belite Bio, LLC (US) | 2024-03-27 | — | — | EP | claimed |
| CN-117440774-A | Biomarkers of age-related macular degeneration | 倍亮生物有限责任公司 | 2024-01-23 | — | — | CN | claimed |
| WO-2023200766-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO, INC (US) | 2023-10-19 | — | — | WO | claimed |
| EP-2295406-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-04-23 | — | — | EP | claimed |
| US-8338622-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | claimed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | claimed |
| EP-2295406-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-16 | — | — | EP | claimed |
| US-20250241902-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO INC (US) | 2025-07-31 | — | — | US | disclosed |
| US-20240248099-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | BELITE BIO, LLC | 2024-07-25 | — | — | US | disclosed |
| EP-4340701-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | Belite Bio, LLC (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-117440774-A | Biomarkers of age-related macular degeneration | 倍亮生物有限责任公司 | 2024-01-23 | — | — | CN | disclosed |
| WO-2023200766-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO, INC (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2295406-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-16 | — | — | EP | disclosed |
| EP-2295406-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-16 | — | — | EP | disclosed |
| WO-2009145286-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241902-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | PDE6C, SERPINA6, PDE6H | NOTUM 2456/4885DPP4 1997/4885SLC6A9 4691/4885 |
| US-20240248099-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | AGER, RBP4, RBP1 | NOTUM 4514/4885DPP4 913/4885SLC6A9 4404/4885 |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | NES, BMI1, DOT1L | NOTUM 874/4885DPP4 1356/4885SLC6A9 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.